Fig. 7: RNF20 can promote RAD51 loading and HR repair in a ligase-independent manner.

a, b Immunostaining and quantification of γH2AX foci number along with the recovery post VP-16 treatment in indicated Hela cells. The WT cells or RNF20 shRNA cells transfected with an empty vector or the plasmid expressing the full-length RNF20 or RNF20-RDΔallele were used for experiments. Cells were treated with VP-16(10 μM) for 1 h and then recovered in fresh media. Cells were collected at indicated time points and stained with DAPI or the antibody against γH2AX for immunofluorescence analysis. Data were the mean ± SD of three independent experiments (n = 3). c, d Immunostaining and quantification of hRad51 foci formation in indicated Hela cells at 1 h after VP-16(10 μM) treatment. Cells were stained with DAPI and the antibody against hRad51 or γH2AX. Data were the mean ± SD of three independent experiments (n = 3). e Plot showing the HR efficiency measured with the DR-GFP reporter for indicated U2OS cell lines. Data are the mean ± SD of three independent experiments (n = 3). f Survival curve for the control or indicated Hela cells upon exposure to indicated doses of VP-16 treatment. Data were the mean ± SD of three independent experiments (n = 3). n.s. no significance; *p < 0.05, **p < 0.01, ***p < 0.001 (Student t-test, two-tailed). Source data are provided as a Source Data file.